Table 2
Assessment of the clinical variables of the parkinsonian patients
| M−1 | M+3 | M+16 | p Value* | |
| LEDD (mg/day) | 1135.4 (91.4) | 622.4 (55.4) | 741.1 (68.5) | <0.001 |
| UPDRS III M “off”/S “off” | 31.5 (2.0) | 33.8 (3.0) | 34.4 (1.7) | NS |
| UPDRS III M “off”/S “on” | 12.9 (1.5) | 16.3 (1.4) | NS | |
| UPDRS III M “on”/S “off” | 6.5 (0.8) | 11.0 (1.3) | 9.3 (0.9) | NS |
| UPDRS III M “on” S “on” | 6.8 (0.9) | 8.9 (0.9) | NS | |
| Hoehn and Yahr “off” | 2.4 (0.1) | 1.9 (0.1) | 2.3 (0.1) | NS |
| Hoehn and Yahr “on” | 1.7 (0.2) | 1.5 (0.2) | 1.6 (0.2) | NS |
| LID duration | 1.5 (0.2) | 0.3 (0.1) | 0.1 (0.1) | <0.001 |
| LID severity | 1.3 (0.2) | 0.1 (0.1) | 0.1 (0.1) | <0.01 |
| “Off” period duration | 1.6 (0.1) | 0.6 (0.1) | 0.9 (0.1) | <0.01 |
| UPDRS I | 1.3 (0.2) | 1.1 (0.2) | 1.6 (0.4) | NS |
| UPDRS II “off” | 17.0 (0.8) | 10.11 (1.0) | 12.3 (0.9) | <0.001 |
| UPDRS II “on” | 3.5 (0.7) | 5.6 (0.8) | 7.9 (0.6) | <0.001 |
-
p Values were calculated by Friedman analysis for multiple comparisons.
-
LID, levodopa induced dyskinesia; LEDD, levodopa equivalent daily dose; M, medication; S, stimulation; UPDRS, Unified Parkinson Disease Rating Scale.
